Last reviewed · How we verify

Standard chemotherapy CHOP + Ritiximab

University of Giessen · Phase 3 active Small molecule

CHOP chemotherapy combined with rituximab kills cancer cells through cytotoxic chemotherapy while rituximab targets CD20+ B cells via antibody-mediated cellular destruction.

CHOP chemotherapy combined with rituximab kills cancer cells through cytotoxic chemotherapy while rituximab targets CD20+ B cells via antibody-mediated cellular destruction. Used for B-cell non-Hodgkin lymphoma, Diffuse large B-cell lymphoma (DLBCL).

At a glance

Generic nameStandard chemotherapy CHOP + Ritiximab
Also known asEndoxan(R), Cyclostin(R) = Cyclophosphamide, Adriamycin(R) Doxorubicin, Oncovin(R) Vincristine, Prednison, Rituxan(R), MabThera(R) = Rituximab
SponsorUniversity of Giessen
Drug classChemotherapy regimen + monoclonal antibody
TargetCD20 (rituximab component); DNA/cell cycle (CHOP component)
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) is a multi-agent chemotherapy regimen that damages DNA and disrupts cell division in rapidly dividing cancer cells. Rituximab is a chimeric monoclonal antibody that binds to CD20 antigen on B cells, triggering antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Together, this combination targets both the malignant B-cell population and provides broad cytotoxic effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: